A Double Blinded Study to Examine the Effect of Coated Suppositories on Fecal Incontinence in Patients With Spinal Cord Injury
The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2011 by RDD Pharma Ltd.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
RDD Pharma Ltd
Information provided by:
RDD Pharma Ltd
ClinicalTrials.gov Identifier:
NCT01297608
First received: February 15, 2011
Last updated: April 5, 2011
Last verified: April 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This is a double blinded cross over study. Approximately 20 spinal cord injury patients will be participating in this 4 weeks study.The primary outcome is difference in fecal incontinence as recorded in diaries, between the treatment period and the treatment period.
| Condition | Intervention | Phase |
|---|---|---|
|
Fecal Incontinenece |
Drug: caoted suppository Drug: coated suppository |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
Resource links provided by NLM:
Further study details as provided by RDD Pharma Ltd:
Primary Outcome Measures:
- fecal incontinence [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- quality of life [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 20 |
| Study Start Date: | April 2011 |
| Estimated Study Completion Date: | September 2011 |
| Estimated Primary Completion Date: | August 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: treatment |
Drug: caoted suppository
coated suppository with active drug
Drug: coated suppository
coated suppository with placebo
|
| Placebo Comparator: placebo |
Drug: coated suppository
coated suppository with placebo
|
Eligibility| Ages Eligible for Study: | 18 Years to 55 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
Signed written informed consent; Male or female subjects 18 to 55 years of age; Spinal cord lesion/disease/injury at any level at least 3 months from injury. FISI (Fecal Incontinence Severity Index) > 8 units. The patient is able to understand the treatment and is willing to comply with the prescribed regimen
Exclusion Criteria:
- Known allergy to experimental drug..
- Porphiria.
- Glaucoma.
- Pregnancy or lactation.
- Active or past history of cardiovascular or cerebrovascular disease including unstable angina, myocardial infarction, transient ischemic attacks/stroke, clinically significant arrhythmia, congestive heart failure, or cardiac valve abnormalities;
- Type 1 diabetes mellitus;
- Insulin treated type 2 diabetes mellitus.
- Renal insufficiency.
- Liver insufficiency.
- Malignant disease within 5 years of screening;
- Has hypertension (sitting blood pressure > 140/90 mmHg at screening)
- History of rectal surgery.
- History of HIV, hepatitis B, hepatitis.
- Has used, in the last four weeks, drugs that may affect blood coagulation, such as Aspirin (at a dose above 250 mg/day), Warfarin, Sintrom, Enoxaparin, Nadroparin, Heparin, Clopidogrel, Ticlopidine.
- Use of tricyclic or monoamine-oxidase inhibors.
- Has upon physical examination a rectal deformation or signs of rectal disease such as fissure, bleeding hemorrhoids, fistula, infection or space occupying lesion.
- Unable to understand the use instruction for the coated suppository, as judged by the investigator.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01297608
Contacts
| Contact: Margarita Zalmanovitz | margaritaz@asaf.health.gov.il |
Locations
| Israel | |
| Gastroeneterology dept, Asaf harofe Medical center | Recruiting |
| Zrifin, Israel | |
| Contact: Margarit Zorkoro +972-8-9779722 margaritaz@asaf.health.gov.il | |
Sponsors and Collaborators
RDD Pharma Ltd
More Information
No publications provided
| Responsible Party: | Nir Barak, RDD Pharma |
| ClinicalTrials.gov Identifier: | NCT01297608 History of Changes |
| Other Study ID Numbers: | RDD 106 |
| Study First Received: | February 15, 2011 |
| Last Updated: | April 5, 2011 |
| Health Authority: | Israel: Ethics Commission |
Additional relevant MeSH terms:
|
Fecal Incontinence Spinal Cord Injuries Rectal Diseases Intestinal Diseases Gastrointestinal Diseases Digestive System Diseases |
Spinal Cord Diseases Central Nervous System Diseases Nervous System Diseases Trauma, Nervous System Wounds and Injuries |
ClinicalTrials.gov processed this record on June 17, 2013